Why the study?
Tricuspid valve disease is the most frequent valvulopathy after heart transplantation, but evidence regarding the negative effect of post-transplant tricuspid regurgitation on survival remains contradictory.
Does the development of moderate or severe tricuspid regurgitation influence survival in heart transplant recipients?
Does the development of moderate or severe tricuspid regurgitation influence survival in heart transplant recipients?
Moderate or severe tricuspid regurgitation after heart transplantation is relatively frequent (19.8%) and is independently associated with an increased risk of mortality or retransplantation, particularly when caused by primary graft failure or rejection.
Moderate-severe TR post-transplant signals higher mortality/retransplant risk; hypothesis-generating in this cohort and needs prospective validation.
Background: Tricuspid valve disease is the most frequent valvulopathy after heart transplantation (HTx). Evidence for the negative effect of post-transplant tricuspid regurgitation (TR) on survival is contradictory. The aim of this study was to analyze the causes of post-transplant TR and its effect on overall mortality. Methods: This is a retrospective observational study of all transplants performed in two Spanish centers (1009 patients) between 2000 and 2019. Of the total number of patients, 809 had no TR or mild TR and 200 had moderate or severe TR. The etiology of TR was analyzed in all cases. Results: The prevalence of moderate and severe TR was 19.8%. The risk of mortality was greater when TR was caused by early primary graft failure (PGF) or rejection (p < 0.05). TR incidence was related to etiology: incidence of PGF-induced TR was higher in the first period, while TR due to rejection and undefined causes occurred more frequently in three periods: in the first year, in the 10–14-year period following HTx, and in the long term (16–18 years). In the multivariable analysis, TR was significantly associated with mortality/retransplantation (HR:1.04, 95% CI:1.01–1.07, p:0.02). Conclusion: The development of TR after HTx is relatively frequent. The annual incidence depends on TR severity and etiology. The risk of mortality is greater in severe TR due to PGF or rejection.
No takes yet. Share an insight, caveat, or question.
López‐Vilella et al. (2022) studied this question.